当前位置:首页 - 行情中心 - 恩华药业(002262) - 财务分析 - 利润表

恩华药业

(002262)

  

流通市值:193.19亿  总市值:220.76亿
流通股本:8.82亿   总股本:10.08亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入3,655,985,179.262,400,328,791.851,178,806,488.434,298,513,062.14
营业收入3,655,985,179.262,400,328,791.851,178,806,488.434,298,513,062.14
二、营业总成本2,660,054,429.071,774,122,216.02909,691,076.333,358,817,486.31
营业成本983,158,637.28630,181,270.64314,403,655.181,020,461,005.81
税金及附加49,281,900.3432,979,020.7616,761,397.7757,462,543
销售费用1,101,292,675.96782,565,128.06420,690,790.821,654,853,866.52
管理费用151,536,044.4594,609,546.2350,680,200.35192,572,271.11
研发费用384,712,055.91237,783,256.56109,676,566.12454,251,728.35
财务费用-9,926,884.87-3,996,006.23-2,521,533.91-20,783,928.48
其中:利息费用3,188,980.182,281,372.05460,236.094,947,486.7
其中:利息收入13,855,152.226,640,869.533,901,362.7525,527,556.12
加:投资收益37,313,681.125,240,612.9915,867,492.3136,272,835.11
资产处置收益-215,578.330,343.130,343.1373,538.47
资产减值损失(新)-19,252,233.13-11,576,802.26-7,938,681.09-16,189,283.51
信用减值损失(新)-13,437,978.9-17,289,395.88-16,664,681.66-3,583,904.53
其他收益5,118,234.863,480,710.641,169,674.2546,896,734.05
营业利润平衡项目0000
四、营业利润1,005,456,875.82626,092,044.42261,579,559.011,003,465,495.42
加:营业外收入635,758.79-122,091.8-1,022,267.572,529,714.51
减:营业外支出5,317,794.923,980,171.312,057,581.2916,088,323.23
利润总额平衡项目0000
五、利润总额1,000,774,839.69621,989,781.31258,499,710.15989,906,886.7
减:所得税费用117,360,174.3577,581,388.3333,326,313.96109,518,333.6
六、净利润883,414,665.34544,408,392.98225,173,396.19880,388,553.1
持续经营净利润-544,408,392.98-880,388,553.1
归属于母公司股东的净利润885,641,307.43544,703,014227,429,413.46900,926,029.55
少数股东损益-2,226,642.09-294,621.02-2,256,017.27-20,537,476.45
(一)基本每股收益0.880.540.230.89
(二)稀释每股收益0.880.540.230.89
八、其他综合收益---2,152,181.79
归属于母公司股东的其他综合收益---2,152,181.79
九、综合收益总额883,414,665.34544,408,392.98225,173,396.19882,540,734.89
归属于母公司股东的综合收益总额885,641,307.43544,703,014227,429,413.46903,078,211.34
归属于少数股东的综合收益总额-2,226,642.09-294,621.02-2,256,017.27-20,537,476.45
公告日期2023-10-262023-07-312023-04-142023-03-21
审计意见(境内)标准无保留意见
TOP↑